186 related articles for article (PubMed ID: 30979571)
1. Lessons for general vaccinology research from attempts to develop an HIV vaccine.
Shapiro SZ
Vaccine; 2019 Jun; 37(26):3400-3408. PubMed ID: 30979571
[TBL] [Abstract][Full Text] [Related]
2. In pursuit of an HIV vaccine: an interview with Andrew McMichael.
McMichael AJ
BMC Biol; 2013 May; 11():60. PubMed ID: 23692824
[No Abstract] [Full Text] [Related]
3. Systems vaccinology: its promise and challenge for HIV vaccine development.
Nakaya HI; Pulendran B
Curr Opin HIV AIDS; 2012 Jan; 7(1):24-31. PubMed ID: 22156839
[TBL] [Abstract][Full Text] [Related]
4. The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses.
Ringel O; Vieillard V; Debré P; Eichler J; Büning H; Dietrich U
Viruses; 2018 Apr; 10(4):. PubMed ID: 29662026
[TBL] [Abstract][Full Text] [Related]
5. Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference.
Ross AL; Bråve A; Scarlatti G; Manrique A; Buonaguro L
Lancet Infect Dis; 2010 May; 10(5):305-16. PubMed ID: 20417413
[TBL] [Abstract][Full Text] [Related]
6. Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions.
Ng'uni T; Chasara C; Ndhlovu ZM
Front Immunol; 2020; 11():590780. PubMed ID: 33193428
[TBL] [Abstract][Full Text] [Related]
7. HIV-specific antibody-dependent cellular cytotoxicity: a novel vaccine modality.
Madhavi V; Kent SJ; Stratov I
Expert Rev Clin Immunol; 2012 Nov; 8(8):767-74. PubMed ID: 23167688
[TBL] [Abstract][Full Text] [Related]
8. Is an HIV vaccine possible?
Wilson NA; Watkins DI
Braz J Infect Dis; 2009 Aug; 13(4):304-10. PubMed ID: 20231996
[TBL] [Abstract][Full Text] [Related]
9. Fundamental challenges to the development of a preventive HIV vaccine.
Rios A
Curr Opin Virol; 2018 Apr; 29():26-32. PubMed ID: 29549802
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
[TBL] [Abstract][Full Text] [Related]
11. Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost.
Virnik K; Nesti E; Dail C; Scanlan A; Medvedev A; Vassell R; McGuire AT; Stamatatos L; Berkower I
Vaccine; 2018 Aug; 36(34):5166-5172. PubMed ID: 30037665
[TBL] [Abstract][Full Text] [Related]
12. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
Sadanand S; Suscovich TJ; Alter G
Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
[TBL] [Abstract][Full Text] [Related]
13. Advancing an HIV vaccine; advancing vaccinology.
Burton DR
Nat Rev Immunol; 2019 Feb; 19(2):77-78. PubMed ID: 30560910
[TBL] [Abstract][Full Text] [Related]
14. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
[TBL] [Abstract][Full Text] [Related]
16. [The new vaccine challenges of "humanization" of HIV].
Nau JY
Rev Med Suisse; 2013 Aug; 9(394):1490-1. PubMed ID: 24024395
[No Abstract] [Full Text] [Related]
17. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
[TBL] [Abstract][Full Text] [Related]
18. Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models.
Pollara J; Jones DI; Huffman T; Edwards RW; Dennis M; Li SH; Jha S; Goodman D; Kumar A; LaBranche CC; Montefiori DC; Fouda GG; Hope TJ; Tomaras GD; Staats HF; Ferrari G; Permar SR
J Virol; 2019 May; 93(10):. PubMed ID: 30842326
[TBL] [Abstract][Full Text] [Related]
19. Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses.
Heeney JL
Expert Rev Vaccines; 2004 Aug; 3(4 Suppl):S53-64. PubMed ID: 15285705
[TBL] [Abstract][Full Text] [Related]
20. A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses.
Perdiguero B; Sánchez-Corzo C; Sorzano COS; Saiz L; Mediavilla P; Esteban M; Gómez CE
Viruses; 2019 Feb; 11(2):. PubMed ID: 30781504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
